HemaCare Corp.'s board has voted to extend to Oct. 21, 1992,the expiration date of the company's 700,000 warrantsoutstanding. The warrants, which were issued as part of thecompany's 1986 initial public offering, were due to expire onOct. 21 of this year.
The exercise terms remain unchanged. Each warrant may beused to purchase one share of common stock at $3.50. TheSherman Oaks, Calif., company may redeem the warrants afterthe market price of the common stock has equaled or exceeded$5.25 for a specified period.
Stock of HemaCare (NASDAQ:HEMA), which made theannouncement on Thursday, closed unchanged at $1.56. Thecompany provides hemapheresis-derived products and servicesand is conducting clinical trials of its passive hyperimmunetherapy to treat AIDS/ARC.
(c) 1997 American Health Consultants. All rights reserved.